Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Jefferson Research

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bristol-Myers Squibb Co Announces Worldwide Discovery Alliance With Santaris Pharma A/S For RNA-Targeted Medicines

Tuesday, 16 Apr 2013 02:00am EDT 

Bristol-Myers Squibb Co announced a worldwide strategic alliance with Santaris Pharma A/S, to discover and develop medicines using Santaris Pharma's Locked Nucleic Acid (LNA) Drug Platform. Under the terms of the agreement, Santaris Pharma will receive an upfront payment of $10 million, up to $90 million in potential payments per product and funding of ongoing discovery and research activities. In addition, Santaris Pharma will be eligible to receive royalties on the worldwide sales of all medicines arising from the alliance. 

Company Quote

-0.01 -0.02%
24 Dec 2014